Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Özdemir Ö, et al. Among authors: sari m. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. Anticancer Drugs. 2022. PMID: 35703239
Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial.
Demir A, Mandel NM, Paydas S, Demir G, Er Ö, Turhal NS, Bavbek S, Eralp Y, Saip PM, Güler EN, Aydıner A, Oyan Uluç B, Kılıçkap S, Üskent N, Karadurmuş N, Kaplan MA, Yanmaz MT, Demir H, Alan Ö, Korkmaz T, Olgun P, Sönmez Uysal Ö, Altundağ K, Gündüz Ş, Günaldı M, Sarı M, Beypınar İ, Başaran G. Demir A, et al. Among authors: sari m. Balkan Med J. 2020 Feb 28;37(2):104-107. doi: 10.4274/balkanmedj.galenos.2020.2019.11.143. Epub 2020 Jan 23. Balkan Med J. 2020. PMID: 31970972 Free PMC article.
PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score.
Bayoğlu İV, Hüseynov J, Topal A, Sever N, Majidova N, Çelebi A, Yaşar A, Arıkan R, Işık S, Hacıoğlu MB, Ercelep Ö, Sarı M, Erdoğan B, Hacıbekiroğlu İ, Topaloğlu S, Köstek O, Çiçin İ. Bayoğlu İV, et al. Among authors: sari m. J Clin Med. 2023 Oct 9;12(19):6420. doi: 10.3390/jcm12196420. J Clin Med. 2023. PMID: 37835062 Free PMC article.
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O, Demirel A, Hacıoğlu MB, Tastekin D, Karabulut S, Gündogdu A, Sever N, Ayhan M, Çelebi A, Majidova N, Yaşar A, Ağyol Y, Erel P, Kocaaslan E, Güren AK, Arıkan R, Isık S, Ercelep O, Goksu SS, Alandag C, Bilgetekin İ, Caner B, Sahin AB, Gulmez A, Akagunduz B, Kose F, Kaplan MA, Dogan E, Sakalar T, Guven DC, Gurbuz M, Ergun Y, Karaagac M, Turker S, Ozkul O, Yıldız B, Sahin S, Demiray AG, Sari M, Erdogan B, Hacıbekiroglu İ, Çakmak Öksüzoğlu ÖB, Kilickap S, Bilici A, Bayoglu İV, Topaloglu S, Cicin İ. Köstek O, et al. Among authors: sari m. J Chemother. 2024 Jan 23:1-9. doi: 10.1080/1120009X.2024.2305066. Online ahead of print. J Chemother. 2024. PMID: 38263804
482 results